A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).
DISEASE(S): Metastatic Colorectal Cancer,Histologically Confirmed Adenocarcinoma Of The Colon Or Rectum That Is Metastatic (stage Iv).,Colorectal Cancer,Colorectal Neoplasms,Neoplasms
PROVIDER: 2213684 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA